Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 May 26;26(11):5096.
doi: 10.3390/ijms26115096.

Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review

Irene Hernández de Córdoba  1 , Xabier Mielgo-Rubio  2 , Paloma Cejas  3 , Jorge Palomar Ramos  4 , Beatriz Garrido-Rubiales  1 , Sandra Falagán Martínez  1 , Gustavo Rubio Romero  1 , María Morales Parga  1 , Laura Moll Taltavull  1 , Andrea Fernández González  1 , Enrique Casado Sáenz  1 , María Sereno  1   5
Affiliations
Review

Transformation to Neuroendocrine Phenotype in Non-Small-Cell Lung Carcinoma: A Literature Review

Irene Hernández de Córdoba et al. Int J Mol Sci. .

Abstract

Neuroendocrine transformation in non-small-cell lung cancer (NSCLC) is an uncommon but clinically significant resistance mechanism to targeted therapy, immunotherapy, and chemotherapy. This phenomenon, primarily observed in adenocarcinoma (ADC) with EGFR mutations under tyrosine kinase inhibitor (TKI) treatment, leads to histological transformation into small-cell lung cancer (SCLC), commonly associated with an aggressive clinical course and poor prognosis. Standard platinum-etoposide chemotherapy provides only transient disease control, highlighting the urgent need for improved therapeutic strategies. Early identification of transformation through biopsy, liquid biopsy, or biomarkers like neuron-specific enolase (NSE) and pro-gastrin-releasing peptide (pro-GRP) may allow for early intervention. As targeted therapies continue to develop, understanding the molecular drivers of neuroendocrine transformation is crucial for optimizing treatment. Further research into novel treatment approaches, including combination therapies with TKIs, chemotherapy, immunotherapy, and epigenetic modulators, is required to improve outcomes for these patients.

Keywords: Rb1; TP53; neuroendocrine transformation; non-small-cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Targeted treatment against NSCLC histology selected the SCLC clone, making it dominant.
Figure 2
Figure 2
Different mechanisms of transformation to a NE phenotype described in the context of EGFR disease.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. - DOI - PubMed
    1. Pikor L.A., Ramnarine V.R., Lam S., Lam W.L. Genetic alterations defining NSCLC subtypes and their therapeutic implications. Lung Cancer. 2013;82:179–189. doi: 10.1016/j.lungcan.2013.07.025. - DOI - PubMed
    1. Zakowski M.F., Ladanyi M., Kris M.G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N. Engl. J. Med. 2006;355:213–215. doi: 10.1056/NEJMc053610. - DOI - PubMed
    1. Chen X., Shao Y., Wei W., Zhu S., Li Y., Chen Y., Li H., Tian H., Sun G., Niu Y., et al. Correction: Androgen deprivation restores ARHGEF2 to promote neuroendocrine differentiation of prostate cancer. Cell Death Dis. 2022;13:927. doi: 10.1038/s41419-022-05366-8. Erratum in Cell Death Dis. 2023, 14, 647. - DOI - PMC - PubMed
    1. Ferrer L., Levra M.G., Brevet M., Antoine M., Mazieres J., Rossi G., Chiari R., Westeel V., Poudenx M., Letreut J., et al. A brief report of transformation from NSCLC to SCLC: Molecular and therapeutic characteristics. J. Thorac. Oncol. 2019;14:130–134. doi: 10.1016/j.jtho.2018.08.2028. - DOI - PubMed

MeSH terms

Substances